These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 26186100)

  • 1. Dissecting the indirect effects caused by vaccines into the basic elements.
    Scarbrough Lefebvre CD; Terlinden A; Standaert B
    Hum Vaccin Immunother; 2015; 11(9):2142-57. PubMed ID: 26186100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Progress in assessment of vaccine on herd protection].
    Jin PF; Li JX; Zhu FC
    Zhonghua Liu Xing Bing Xue Za Zhi; 2018 Jun; 39(6):862-866. PubMed ID: 29936762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
    Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
    BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosenescence and herd immunity: with an ever-increasing aging population do we need to rethink vaccine schedules?
    Lang PO; Aspinall R
    Expert Rev Vaccines; 2012 Feb; 11(2):167-76. PubMed ID: 22309666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine herd effect.
    Kim TH; Johnstone J; Loeb M
    Scand J Infect Dis; 2011 Sep; 43(9):683-9. PubMed ID: 21604922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.
    Isaacman DJ; Strutton DR; Kalpas EA; Horowicz-Mehler N; Stern LS; Casciano R; Ciuryla V
    Clin Ther; 2008 Feb; 30(2):341-57. PubMed ID: 18343273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New approaches to the assessment of vaccine herd protection in clinical trials.
    Clemens J; Shin S; Ali M
    Lancet Infect Dis; 2011 Jun; 11(6):482-7. PubMed ID: 21616458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Herd immunity and pneumococcal conjugate vaccine: a quantitative model.
    Haber M; Barskey A; Baughman W; Barker L; Whitney CG; Shaw KM; Orenstein W; Stephens DS
    Vaccine; 2007 Jul; 25(29):5390-8. PubMed ID: 17583392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protecting the Community Through Child Vaccination.
    Anderson EJ; Daugherty MA; Pickering LK; Orenstein WA; Yogev R
    Clin Infect Dis; 2018 Jul; 67(3):464-471. PubMed ID: 29471452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2003 to 2006.
    Menzies R; Turnour C; Chiu C; McIntyre P
    Commun Dis Intell Q Rep; 2008 Jun; 32 Suppl():S2-67. PubMed ID: 18711998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
    Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
    Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of surveillance in assuring mutual protection for vaccine-preventable diseases.
    Lopalco PL
    Clin Microbiol Infect; 2016 Dec; 22 Suppl 5():S85-S88. PubMed ID: 27476865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Herd immunity: recent uses in vaccine assessment.
    Gonçalves G
    Expert Rev Vaccines; 2008 Dec; 7(10):1493-506. PubMed ID: 19053206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
    Melegaro A; Edmunds WJ
    Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pneumococcal serotype distribution in adults with invasive disease and in carrier children in Italy: Should we expect herd protection of adults through infants' vaccination?
    Azzari C; Cortimiglia M; Nieddu F; Moriondo M; Indolfi G; Mattei R; Zuliani M; Adriani B; Degl'Innocenti R; Consales G; Aquilini D; Bini G; Di Natale ME; Canessa C; Ricci S; de Vitis E; Mangone G; Bechini A; Bonanni P; Pasinato A; Resti M
    Hum Vaccin Immunother; 2016; 12(2):344-50. PubMed ID: 26647277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.
    Lloyd A; Patel N; Scott DA; Runge C; Claes C; Rose M
    Eur J Health Econ; 2008 Feb; 9(1):7-15. PubMed ID: 17333089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine impact: Benefits for human health.
    Doherty M; Buchy P; Standaert B; Giaquinto C; Prado-Cohrs D
    Vaccine; 2016 Dec; 34(52):6707-6714. PubMed ID: 27773475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2006-2010.
    Naidu L; Chiu C; Habig A; Lowbridge C; Jayasinghe S; Wang H; McIntyre P; Menzies R
    Commun Dis Intell Q Rep; 2013 Dec; 37 Suppl():S1-95. PubMed ID: 24410428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.